A case study of 10 patients administered HBOC‐201 in high doses over a prolonged period: outcomes during severe anemia when transfusion is not an option

Autor: Garry Schwartz, Mauricio Lynn, Kim Hien T. Dao, Katherine Walsh, Jed B. Gorlin, Marc Zumberg, Amanda M. VanSandt, Elizabeth A. Griffiths, Aryeh Shander, Bradley S. Fletcher

Publikováno v: Transfusion. 60:932-939

BACKGROUND Hemoglobin-Based Oxygen Carriers (HBOCs) can act as an "oxygen bridge" in acute severe anemia when transfusion is indicated, but not possible. We present data on 10 Expanded Access (EA) patients treated with high cumulative doses of Hemopu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::326301ae90360dc606ba4659eac97ff2
https://doi.org/10.1111/trf.15778

Integrative Analysis of Drug Response and Clinical Outcome in Acute Myeloid Leukemia

Autor: Daniel Bottomly, Nicola Long, Anna Reister Schultz, Stephen E. Kurtz, Cristina E. Tognon, Kara Johnson, Melissa Abel, Anupriya Agarwal, Sammantha Avaylan, Erik Benton, Aurora Blucher, Uma Borate, Theodore Braun, Jordana Brown, Jade Bryant, Russell Burke, Amy Carlos, Bill H. Chang, Hyun Jun Cho, Stephen Christy, Cody Coblentz, Aaron M. Cohen, Amanda d’Almeida, Rachel Cook, Alexey Danilov, Kim-Hien T. Dao, Michie Degnin, James Dibb, Christopher A. Eide, Isabel A. English, Stuart Hagler, Heath Harrelson, Rachel Henson, Hibery Ho, Sunil Joshi, Brian Junio, Andy Kaempf, Yoko Kosaka, Ted Laderas, Matt Lawhead, Hyunjung Lee, Jessica T. Leonard, Chenwei Lin, Evan F. Lind, Selina Qiuying Liu, Pierrette Lo, Marc M. Loriaux, Samuel Luty, Julia E. Maxson, Tara Macey, Jacqueline Martinez, Jessica Minnier, Andrea Monteblanco, Motomi Mori, Quinlan Morrow, Dylan Nelson, Justin Ramsdill, Angela Rofelty, Alexandra Rogers, Peter Ryabinin, Jennifer N. Saultz, David A. Sampson, Samantha L. Savage, Robert Schuff, Robert Searles, Rebecca L. Smith, Stephen E. Spurgeon, Tyler Sweeney, Ronan T. Swords, Aashis Thapa, Karina Thiel-Klare, Elie Traer, Jake Wagner, Beth Wilmot, Joelle Wolf, Guanming Wu, Amy Yates, Haijiao Zhang, Christopher Cogle, Robert H. Collins, Michael W. Deininger, Christopher S. Hourigan, Craig T. Jordan, Tara L. Lin, Micaela E. Martinez, Rachel R. Pallapati, Daniel Pollyea, Tony Pomicter, Justin M. Watts, Scott Weir, Brian J. Druker, Shannon K. McWeeney, Jeffrey W. Tyner

Publikováno v: SSRN Electronic Journal.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9cb02f596cf7945b6c746e259cdd2427
https://doi.org/10.2139/ssrn.4041405

Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia

Autor: Kim-Hien T. Dao, Magdolna B. Solti, Julia E. Maxson, Elliott F. Winton, Richard D. Press, Brian J. Druker, Jeffrey W. Tyner

Publikováno v: Leukemia Research Reports, Vol 3, Iss 2, Pp 67-69 (2014)

Mutations in CSF3R (colony-stimulating factor 3 receptor) are frequent oncogenic drivers in chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML). Here we describe a 75 year old man who was diagnosed with CSF3R-T618I-positi

Externí odkaz: https://doaj.org/article/6a02e636133c40769b55da364c50e950

Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years

Autor: Rachel J. Cook, Gabrielle Meyers, Richard T. Maziarz, Elie Traer, Uma Borate, Laura F. Newell, Kim Hien T. Dao, Jessica Leonard, Curtis Lachowiez, Brandon Hayes-Lattin

Publikováno v: Hematology/Oncology and Stem Cell Therapy, Vol 12, Iss 2, Pp 105-109 (2019)

Allogeneic hematopoietic stem cell transplantation (HSCT) is an integral therapy for patients with hematological malignancies, myelodysplasia, and bone marrow failure. Its use has been increasing over the past decade, as understanding of the treatmen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c2bd1bce19c14577da83974f03396ab
https://doi.org/10.1016/j.hemonc.2019.01.002

Functional genomic landscape of acute myeloid leukaemia

Autor: Robert H. Collins, Deirdre Devine, Beth Wilmot, Justin Ramsdill, Erik Segerdell, Bruno C. Medeiros, Brian J. Druker, Dylan Nelson, Micaela E. Martinez, Ryan C. Johnson, Robert Schuff, Robert P. Searles, Scott Weir, James Dibb, Elie Traer, Pierrette Lo, Haijiao Zhang, Rachel Henson, Tara A. Macey, Isabel English, Cody Coblentz, Christopher A. Eide, Ceilidh Nichols, Aurora Blucher, Ryan M. Winters, David L. Wiest, Corinne Visser, Michael W. Deininger, Stephen E. Kurtz, Daniel A. Pollyea, Justin M. Watts, Amy S. Carlos, Denise C. Connolly, Andy Kaempf, Angela Rofelty, Samuel B. Luty, Rachel J. Cook, Jill Peters, Kristen Werth, Shannon K. McWeeney, Joseph Carroll, Samantha L. Savage, Ronan T. Swords, Uma Borate, Aashis Thapa, Abdusebur Jemal, Joelle Wolf, Patricia Kropf, Rebecca Smith, Tyler Sweeney, Russell T. Burke, Rachel R. Pallapati, Anna Reister Schultz, Kim Hien T. Dao, Daniel Bottomly, Cristina E. Tognon, Alexey V. Danilov, Jason M. Glover, Jason D. MacManiman, Michie Degnin, Amy Yates, Libbey White, David K. Edwards, Anupriya Agarwal, Christopher R. Cogle, Kevin Watanabe-Smith, Leylah Drusbosky, Nicola Long, Motomi Mori, Christopher S. Hourigan, Tara L. Lin, Chenwei Lin, Jacqueline Martinez, Bill H. Chang, Richie Carpenter, Stephen E. Spurgeon, Brian Junio, Marc M. Loriaux, Craig T. Jordan, Hibery Ho, Selina Qiuying Liu, Melissa L. Abel, Amanda d’Almeida, Jake Wagner, Jade Bryant, Jeffrey W. Tyner, Jessica Leonard, Kara Johnson

Publikováno v: Nature

The implementation of targeted therapies for acute myeloid leukaemia (AML) has been challenging because of the complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most mutational events. Here we repo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65ec9f74bb9044f4d83aab7c87cd9b94
https://doi.org/10.1038/s41586-018-0623-z